Astellas Pharma Inc. (ALPMF)
USD 10.12
(0.0%)
USD 10.12
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | 282.44 Billion JPY | -42.26% |
| 2023 | 337.39 Billion JPY | 13.52% |
| 2022 | 297.82 Billion JPY | -1.37% |
| 2021 | 323.58 Billion JPY | -30.0% |
| 2020 | 333.87 Billion JPY | 0.33% |
| 2019 | 345.87 Billion JPY | 10.17% |
| 2018 | 336.68 Billion JPY | -18.06% |
| 2017 | 337.6 Billion JPY | 4.5% |
| 2016 | 338.69 Billion JPY | 28.79% |
| 2015 | 292.34 Billion JPY | 37.41% |
| 2014 | 247.39 Billion JPY | -12.7% |
| 2013 | 180.09 Billion JPY | 7.25% |
| 2012 | 200.72 Billion JPY | 2.19% |
| 2011 | 196.42 Billion JPY | -40.73% |
| 2010 | 234.87 Billion JPY | -14.53% |
| 2009 | 336.12 Billion JPY | 23.88% |
| 2008 | 312.98 Billion JPY | 32.46% |
| 2007 | 246.07 Billion JPY | -1.12% |
| 2006 | 238.95 Billion JPY | 69.01% |
| 2005 | 141.38 Billion JPY | 9.59% |
| 2004 | 128.9 Billion JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 37.2 Billion JPY | -41.59% |
| 2024 Q3 | 66.8 Billion JPY | 65.08% |
| 2024 Q4 | 86.36 Billion JPY | 31.15% |
| 2024 Q1 | 72.76 Billion JPY | 399.71% |
| 2024 FY | - JPY | 36.18% |
| 2023 Q2 | 113.15 Billion JPY | 59.88% |
| 2023 Q3 | 85.52 Billion JPY | -24.42% |
| 2023 Q4 | -22.79 Billion JPY | -126.65% |
| 2023 FY | - JPY | 13.52% |
| 2023 Q1 | 70.77 Billion JPY | 535.51% |
| 2022 Q4 | 11.13 Billion JPY | -85.54% |
| 2022 FY | - JPY | -1.37% |
| 2022 Q1 | 55.69 Billion JPY | 22356.05% |
| 2022 Q2 | 73.44 Billion JPY | 31.88% |
| 2022 Q3 | 77.01 Billion JPY | 4.85% |
| 2021 Q3 | 93.8 Billion JPY | 99.31% |
| 2021 Q4 | 248 Million JPY | -99.74% |
| 2021 FY | - JPY | -30.0% |
| 2021 Q1 | 79.19 Billion JPY | 217.2% |
| 2021 Q2 | 47.06 Billion JPY | -40.57% |
| 2020 Q4 | 24.96 Billion JPY | -73.75% |
| 2020 FY | - JPY | 0.33% |
| 2020 Q2 | 99.81 Billion JPY | 5.22% |
| 2020 Q3 | 95.1 Billion JPY | -4.72% |
| 2020 Q1 | 94.86 Billion JPY | 81.58% |
| 2019 Q1 | 80.79 Billion JPY | 59.67% |
| 2019 FY | - JPY | 10.17% |
| 2019 Q2 | 79.99 Billion JPY | -0.98% |
| 2019 Q3 | 100.68 Billion JPY | 25.86% |
| 2019 Q4 | 52.24 Billion JPY | -48.11% |
| 2018 Q3 | 100.23 Billion JPY | 44.9% |
| 2018 FY | - JPY | -18.06% |
| 2018 Q1 | 64.74 Billion JPY | 18.31% |
| 2018 Q2 | 69.17 Billion JPY | 6.84% |
| 2018 Q4 | 50.6 Billion JPY | -49.52% |
| 2017 Q4 | 54.72 Billion JPY | -46.42% |
| 2017 Q3 | 102.14 Billion JPY | 26.28% |
| 2017 FY | - JPY | 4.5% |
| 2017 Q2 | 80.88 Billion JPY | -26.5% |
| 2017 Q1 | 110.05 Billion JPY | 119.39% |
| 2016 FY | - JPY | 28.79% |
| 2016 Q1 | 85.31 Billion JPY | 87.04% |
| 2016 Q4 | 50.16 Billion JPY | -50.51% |
| 2016 Q3 | 101.35 Billion JPY | 5.85% |
| 2016 Q2 | 95.75 Billion JPY | 12.24% |
| 2015 Q1 | 67.84 Billion JPY | 663.15% |
| 2015 Q2 | 69.04 Billion JPY | 1.76% |
| 2015 Q3 | 75.73 Billion JPY | 9.7% |
| 2015 FY | - JPY | 37.41% |
| 2015 Q4 | 45.61 Billion JPY | -39.78% |
| 2014 Q1 | 61.12 Billion JPY | 193.36% |
| 2014 Q3 | 98.37 Billion JPY | 40.24% |
| 2014 Q2 | 70.14 Billion JPY | 14.76% |
| 2014 FY | - JPY | -12.7% |
| 2014 Q4 | -12.04 Billion JPY | -112.25% |
| 2013 Q2 | 34.67 Billion JPY | -37.84% |
| 2013 Q3 | 46.12 Billion JPY | 33.03% |
| 2013 Q4 | 20.83 Billion JPY | -54.83% |
| 2013 FY | - JPY | 7.25% |
| 2013 Q1 | 55.78 Billion JPY | 733.5% |
| 2012 FY | - JPY | 2.19% |
| 2012 Q1 | 51.67 Billion JPY | 118.08% |
| 2012 Q2 | 27.56 Billion JPY | -46.65% |
| 2012 Q4 | -8.8 Billion JPY | -113.59% |
| 2012 Q3 | 64.78 Billion JPY | 135.0% |
| 2011 Q3 | 72.4 Billion JPY | 122.1% |
| 2011 Q2 | 32.6 Billion JPY | -51.86% |
| 2011 Q1 | 67.72 Billion JPY | -39.09% |
| 2011 FY | - JPY | -40.73% |
| 2011 Q4 | 23.69 Billion JPY | -67.27% |
| 2010 Q3 | 68.5 Billion JPY | -4.48% |
| 2010 FY | - JPY | -14.53% |
| 2010 Q4 | 111.18 Billion JPY | 62.31% |
| 2010 Q1 | 80 Billion JPY | -37.81% |
| 2010 Q2 | 71.71 Billion JPY | -10.37% |
| 2009 FY | - JPY | 23.88% |
| 2009 Q2 | 68.33 Billion JPY | 0.0% |
| 2009 Q3 | 101.25 Billion JPY | 48.17% |
| 2009 Q4 | 128.65 Billion JPY | 27.06% |
| 2008 FY | - JPY | 32.46% |
| 2007 FY | - JPY | -1.12% |
| 2006 FY | - JPY | 69.01% |
| 2005 FY | - JPY | 9.59% |
| 2004 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AstraZeneca PLC | 13.28 Billion USD | -2025.308% |
| Bristol-Myers Squibb Company PFD CONV 2 | 19.41 Billion USD | -1354.633% |
| CSPC Pharmaceutical Group Limited | 1.14 Billion USD | -24501.915% |
| Clarus Therapeutics Holdings, Inc. | -39.7 Million USD | 711461.29% |
| Novartis AG | 19.51 Billion USD | -1347.118% |
| PT Kalbe Farma Tbk. | 288.13 Million USD | -97926.026% |